Probiotic, Lactobacillus rhamnosus GG, in Reducing Gut-derived Uremic Toxins in Non-dialysis Chronic Kidney Disease Patients, A Randomized Controlled Trial

Phase 2

Completed

• Conditions: To study the efficacy of probiotic Lactobacillus rhamnosus GG in reducing gut derived Uremic toxin in chronic kidney disease patients before receiving renalreplacement therapy.; To study the efficacy of probiotic Lactobacillus rhamnosus GG in reducing gut derived Uremic toxin in chronic kidney disease patients before receiving renal; replacement therapy.

• Registration Number: TCTR20210807005
• Lead Sponsor: Ratchadapiseksompotch Research Fund

Brief Summary

actobacillus rhamnosus GG changed the structure of gut microbiome phyla, therefore improved gut dysbiosis, attenuated GDUT production, and reduced inflammatory responses. Probiotics could play a beneficial role in retarding CKD progression in the future.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-07
• Study Completion: 2022-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age > 18 years old
Diagnosed CKD stage 3-5 or estimated glomerular filtration rate (eGFR)
between 10-60 ml/min/mm2 who did not undergo renal replacement therapy

Exclusion Criteria

Estimated glomerular filtration rate (eGFR ) less than 10 ml/min/mm2
History of kidney transplant
On immunosuppressive therapy
History of Renal replace therapy except RRT from acute kidney failure
Pregnancy at date of participation
Diagnosed Inflammatory bowel disease or infection at bowel
Diagnosed Cancer who has to ongoing Chemotherapy or in stage 4
End-stage diseases : Congestive heart failure NYHA 4, End-stage lung diseases, Cirrhosis
Child-Pugh B,C, or patient who has Karnofsky performance score less than 40

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
serum IS, PCS 8 weeks Immunoassay

Secondary Outcome Measures

Name	Time	Method
eGFR (CKD-EPI) 8 wk Blood quantity,IL-6 8 wk Immunoassay,IL-10 8 wk Immunoassay,Endotoxin activity assay 8 wk Endotoxin activity assay,GI symptoms score 8 wk Questionaired